In the News

1852 News Items found
A barred Plymouth Rock hen
Feature
When this feathered patient found her way into a New York laboratory in 1909, she changed the course of cancer science.
Patient on left in chemotherapy infusion chair talking to nurse
Support
Learn about some lesser-known side effects from cancer treatment including falling caused by peripheral neuropathy, fatigue, hormone and sexual changes, and short-term memory problems (chemo brain).
Closeup photograph of a nurse and patient holding hands
Feature
Learn how nurses stay resilient by dealing effectively with stress on the job.
An infographic describing MSK Monmouth's first year
Announcement
A Look Back at MSK Monmouth’s First Year
Discover how MSK Monmouth is making an impact in Middletown, New Jersey.
cryo-EM picture of mTORC1
In the Lab
Structural biologists in the Sloan Kettering Institute have used a powerful tool called cryo-EM to solve the structure of a major cancer player.
Thousands of technology professionals from around the world recently gathered in Long Beach, California, for the sold-out Neural Information Processing Systems (NIPS) conference, a multi-track machine learning, artificial intelligence, and computational neuroscience event featuring talks, demonstrations, symposia and oral / poster presentations, along with several workshops. Leaders in artificial intelligence, machine learning, and data engineering from Memorial Sloan Kettering attended NIPS and announced the winner of a unique competition created by MSK, Classifying Clinically Actionable Genetic Mutations. For more information and to set up interviews or access photos and video, email [email protected].
Welcome sign at the San Antonio Breast Cancer Symposium
In the News
SummaryMore than 20 MSK physicians and researchers presented work at an annual breast cancer conference in San Antonio.The San Antonio Breast Cancer Sy...
In the largest-ever genetic analysis of people being treated with checkpoint inhibitors, Memorial Sloan Kettering researchers looked at patients who received several checkpoint inhibitors for a number of different cancers at many different hospitals. Researchers found that people who had a greater diversity and more variation in their human leukocyte antigen (HLA) genes responded much better to immunotherapy compared with those who had less diversity. For more information or to speak with an expert, contact Rebecca Williams at [email protected].
Model of a T cell receptor and an HLA-A white blood cell antigen bound to part of a virus
Q&A
Immunotherapy drugs called checkpoint inhibitors have been a game changer for some people with cancer. But for most patients, these drugs have been disappointing. Researchers are trying to figure out why.
medical oncologist Larry Norton
Q&A
Dose-dense chemotherapy calls for less time between doses compared with a standard treatment plan.